CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 191 enrolled
Drug / intervention
Travoprost 0.004% BAK-freedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01510145
NCT01510145Phase 4Completed
CompareCT.gov

Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy

Alcon Research·interventional·Posted Jan 13, 2012·Updated Jun 13, 2014

In Brief

A Phase 4 clinical trial evaluating Travoprost 0.004% BAK-free for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 191 participants.

Detailed Summary

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with open-angle glaucoma or ocular hypertension due to tolerability issues.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 13, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.5 years ago

Interventions

Travoprost 0.004% BAK-freedrug

Containing Polyquad (PQ) preservative